+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

Application of a mortality risk score in a general population of patients with an implantable cardioverter defibrillator (ICD)



Application of a mortality risk score in a general population of patients with an implantable cardioverter defibrillator (ICD)



Heart 100(6): 487-491



The implantable cardioverter defibrillator (ICD) is very effective in the prevention of sudden cardiac death, but its benefit is impaired by competing risks. A simple risk model to predict mortality was designed for patients with primary prevention and ischaemic cardiomyopathy. We aimed to apply this score to a general ICD population. This retrospective registry study included all patients in whom an ICD was implanted at a tertiary referral hospital. Risk factors were age >70 years, QRS width >120 ms, atrial fibrillation, New York Heart Association Functional Classification class >2 and glomerular filtration rate <60 mL/min/1.73 m(2). Kaplan-Meier curves were constructed according to the presence of 0, 1, 2 and >2 risk factors. The cohort consists of 1032 patients, 881 (86%) were men, mean age was 61±14 years and mean follow-up 66±46 months. 256 patients (25%) died 58±41 months after implant. The setting was secondary prevention in 498 patients (48%). No risk factors was present in 32% of patients, 1 in 27%, 2 in 20% and >2 in 21%, respectively. There was a significant and comprehensible relation between risk score and mortality. Cumulative survival was 82% in patients with 0 risk factors, 63% in those with 1, 41% in those with 2 and 23% in those with >2 risk factors (p < 0.0001). ICD therapies were documented in 421 patients (41%) without correlation to risk factors. In a mixed population of primary and secondary preventive ICD carriers, application of a simple risk score predicts long-term mortality but not appropriate use of the ICD.

(PDF emailed within 0-6 h: $19.90)

Accession: 051607409

Download citation: RISBibTeXText

PMID: 24415667

DOI: 10.1136/heartjnl-2013-305002



Related references

Application of a mortality risk score in a general population of patients with an Implantable Cardioverter Defibrillator (ICD). European Heart Journal 34(Suppl 1): P1377-P1377, 2013

Correction. Application of a mortality risk score in a general population of patients with an implantable cardioverter defibrillator (ICD). Heart 101(17): 1434-1434, 2015

Pre-implantation implantable cardioverter defibrillator concerns and Type D personality increase the risk of mortality in patients with an implantable cardioverter defibrillator. Europace 12(10): 1446-1452, 2011

Implantable cardioverter-defibrillator registry risk score models for acute procedural complications or death after implantable cardioverter-defibrillator implantation. Circulation 123(19): 2069-2076, 2011

Incidence of appropriate cardioverter-defibrillator shocks and mortality in patients with heart failure treated with combined cardiac resynchronization plus implantable cardioverter-defibrillator therapy versus implantable cardioverter-defibrillator therapy. Journal of Cardiovascular Pharmacology and Therapeutics 15(1): 37-40, 2010

Dual-Chamber Implantable Cardioverter-Defibrillator Selection Is Associated With Increased Complication Rates and Mortality Among Patients Enrolled in the NCDR Implantable Cardioverter-Defibrillator Registry. Yearbook of Cardiology 2012: 462-463, 2012

Dual-chamber implantable cardioverter-defibrillator selection is associated with increased complication rates and mortality among patients enrolled in the NCDR implantable cardioverter-defibrillator registry. Journal of the American College of Cardiology 58(10): 1007-1013, 2011

Clinical risk profile score predicts all cause mortality but not implantable cardioverter defibrillator intervention rate in a large unselected cohort of patients with congestive heart failure. Annals of Noninvasive Electrocardiology 22(3): -, 2016

Do baseline characteristics accurately discriminate between patients likely versus unlikely to benefit from implantable defibrillator therapy? Evaluation of the Canadian implantable defibrillator study implantable cardioverter defibrillatory efficacy score in the antiarrhythmics versus implantable defibrillators trial. American Heart Journal 141(1): 99-104, 2001

Early mortality in prophylactic implantable cardioverter-defibrillator recipients: development and validation of a clinical risk score. Europace 16(1): 40-46, 2014

Statins reduce appropriate cardioverter-defibrillator shocks and mortality in patients with heart failure and combined cardiac resynchronization and implantable cardioverter-defibrillator therapy. Journal of Cardiovascular Pharmacology and Therapeutics 14(3): 176-179, 2009

Mortality risk score in primary prevention implantable cardioverter defibrillator recipients with non-ischaemic or ischaemic heart disease. European Heart Journal 31(6): 712-718, 2011

The Relationship of Antitachycardia Pacing versus Shock in an Implantable Cardioverter-Defibrillator Population and the Risk of Mortality: Just an Association?. Journal of Cardiovascular Electrophysiology 28(4): 423-424, 2017

Use of a regional wall motion score to enhance risk stratification of patients receiving an implantable cardioverter-defibrillator. Journal of the American College of Cardiology 22(4): 1093-1099, 1993

Anxiety and risk of ventricular arrhythmias or mortality in patients with an implantable cardioverter defibrillator. Psychosomatic Medicine 75(1): 36-41, 2013